# Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide

> **NCT03580668** · — · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 201 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** B/F/TAF

## Key facts

- **NCT ID:** NCT03580668
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-13
- **Primary completion:** 2024-06-03
- **Final completion:** 2024-06-03
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580668, "Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03580668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*